MIRA MIRA Pharmaceuticals, Inc.Stock Price & Overview
$0.71
Charts
Quant Ranking
MIRA Analysis
MIRA News
Latest Headlines
People Also Follow
Similar to MIRA
ETFs Holding MIRA
MIRA Company Profile
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.
MIRA Revenue
MIRA Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Profitability
Momentum
Capital Structure
Dividends
MIRA Ownership
MIRA Peers
Risk
Technicals
MIRA SEC Filings
Press Releases
MIRA Income Statement
MIRA Balance Sheet
MIRA Cash Flow Statement
MIRA Long Term Solvency
Discover More
You may be interested in: